INLIGHTA BIOSCIENCES, LLC
Medtech · Private
Collagen-targeted MRI contrast agent (INL-101/ProCA32.collagen) for noninvasive lung fibrosis imaging and staging
- Grants
- $7.8M
- 12 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201620182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Molecular Imaging of Early Stage of Liver Fibrosis by Novel Protein Agents | $238,587 | |
| Federal grant | Department of Health and Human Services · Phase II · Noninvasive Contrast Enhanced Early Detection of Melanoma Liver Metastasis | $602,227 | |
| Federal grant | Department of Health and Human Services · Phase II · Noninvasive Contrast Enhanced Early Detection of Melanoma Liver Metastasis | $728,995 | |
| Federal grant | Department of Health and Human Services · Phase II · Detection and Staging of Liver Fibrosis by Precise MRI (pMRI) | $666,670 | |
| Federal grant | Department of Health and Human Services · Phase II · Noninvasive Contrast Enhanced Early Detection of Melanoma Liver Metastasis | $668,995 | |
| Federal grant | Department of Health and Human Services · Phase II · Detection and Staging of Liver Fibrosis by Precise MRI (pMRI) | $666,672 | |
| Federal grant | Department of Health and Human Services · Phase II · Detection and Staging of Liver Fibrosis by Precise MRI (pMRI) | $666,670 | |
| Federal grant | Department of Health and Human Services · Phase II · Non-invasive staging of Metastasis by Precision MRI | $954,220 | |
| Federal grant | Department of Health and Human Services · Phase II · Non-invasive staging of Metastasis by Precision MRI | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Precision MRI with a Novel Protein Contrast Agent for Early Detection and Staging of Lung Fibrosis | $298,840 | |
| Federal grant | Department of Health and Human Services · Phase I · Design of Calcium-sensing Receptor Targeted Thera(g)nostic Agents | $323,743 | |
| Federal grant | Department of Health and Human Services · Phase II · Precision MRI with Protein Contrast Agent for Noninvasive Detection of Lung Fibrosis | $1,026,874 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2177 | SPEECH TECHNOLOGY/APPLIED RESEARCH CORP. | — | — |
| 2178 | SURAMEDICAL, LLC | — | — |
| 2179 | HYDROGLYDE COATINGS, LLC | — | — |
| 2180 | INLIGHTA BIOSCIENCES, LLC | — | — |
| 2181 | Anelleo, Inc. | — | — |
| 2182 | LEEFA BIOTECH, LLC | — | — |
| 2183 | CALLAHAN-YOUNG LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.